May 03, 2021
After a brief reprieve last month, COVID-19 is dominating our top 10 list once again. Stories exploring rare vaccine-related side effects held the highest rank in April, followed by TCTMD’s Daily Dispatch chronicling pandemic news and research. Nestled among the more-typical topics, including definitions for aortic valve research, anti-inflammatories in CVD, type 2 diabetes, recalls, and the like, is a meta-analysis that confirms COVID-19 patients should continue ACE inhibitors and ARBs. There’s also an exploration of a multidisciplinary, team-based approach for stroke thrombectomy.
1.
May 3, 2021
WASHINGTON, May 3, 2021 – Timothy D. Henry, MD, MSCAI, interventional cardiologist and Lindner Family Distinguished Chair in Clinical Research and medical director of The Carl and Edyth Lindner Center for Research assumed the office of president of the Society for Cardiovascular Angiography and Interventions (SCAI) on May 1 during the Society’s annual Scientific Sessions.
With a career devoted to interventional cardiology and clinical research, Dr. Henry has published more than 550 manuscripts and book chapters. His research interests include interventional cardiology, acute myocardial infarction (AMI), and novel therapies for patients with refractory angina. He has served as principal investigator and steering committees of multiple large, multicenter research trials in acute myocardial infarction and refractory angina. Dr. Henry is the former chief of cardiology at Cedar Sinai Medical Center in Los Angeles, CA and is known as a pioneer in the treatment of Myo
May 03, 2021
Long-term dual antiplatelet therapy (DAPT) reduces ischemic events without a trade-off in bleeding compared with shorter durations among ACS patients who undergo PCI, according to new registry data from China.
The findings, released at the virtual Society for Cardiovascular Angiography and Interventions (SCAI) 2021 meeting, are slightly out of step with the TWILIGHT ACS substudy, which indicated a shorter duration of DAPT followed by ticagrelor monotherapy lowers bleeding risk in these patients without increasing ischemic events. In the Chinese registry, DAPT primarily consisted of clopidogrel and aspirin.
“To the best of our knowledge, this is the first report investigating the feasibility and safety of long-term DAPT for high-risk ‘TWILIGHT-like’ patients with ACS treated with DES,” Hao-Yu Wang, MD (Fuwai Hospital, Beijing, China), said in his presentation. “These results suggested that prolonged DAPT in ACS patients who present with a particularly higher
POLITICO
Get the POLITICO Influence newsletter
Email
Sign Up
By signing up you agree to receive email newsletters or updates from POLITICO and you agree to our privacy policy and terms of service. You can unsubscribe at any time and you can contact us here. This sign-up form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
With Daniel Lippman Doug Jones (D-Ala.) and Cissy Jackson are joining
Arent Fox’s government relations and government enforcement and white collar groups as counsel. Jackson previously was counsel and national security adviser for Jones. Jones said he won t register to lobby but that still leaves incredible opportunities to me to advise clients and help them navigate the political world and the world of D.C. without registering as a lobbyist.
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria
The landmark study only includes small number of these patients who undergo PCI, raising questions about the data and its relation to real-world practice
Getty Images
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for stable ischemic heart disease (SIHD) in the U.S. did not meet enrollment criteria for the ISCHEMIA trial. The data, which was presented as a late-breaking study at the Society for Cardiovascular Angiography and Interventions (SCAI) 2021 virtual meeting, demonstrates that only a minority of SIHD patients referred for coronary intervention in contemporary practice clearly resemble those enrolled in the ISCHEMIA trial.